Board of Directors

William Conkling, has served as President of Rafael Holdings since January 2023 and as its Chief Executive Officer since February 2022. He previously served as the Chief Commercial and Business Officer of Rafael Holdings from March 8, 2021 to January 31, 2022. Mr. Conkling has over 20 years’ experience in the pharmaceutical/biotech industry working in Oncology. He has extensive experience launching innovative oncology products. His experience spans across all areas of ommercialization including marketing, sales, market access, commercial operations and business development. Prior to joining Rafael Holdings, Mr. Conkling helped lead the launch of Trodelvy at Immunomedics Inc. (acquired by Gilead for $21B in October 2020) as the VP Sales, Marketing and Market Access. Mr. Conkling also spent over 10 years at Novartis Oncology where he helped lead the launch of the first CAR-T therapy approved in the US as the Global Commercial Leader — Kymriah. Mr. Conkling earned his Bachelor’s Degree from Fordham University and his Master’s in Business Administration from New York University Stern School of Business in 1998.

 

John Goldberg, MD, has served as Chief Medical Officer of Rafael Holdings since November 2023. Dr. Goldberg is a seasoned medical professional with 18 years of experience in Oncology clinical trials across academia and industry. Dr. Goldberg was the Chief Medical Officer at Oncorus from Feb 2022 to June 2023 and served as Senior Vice President of Clinical Development from Oct 2018 to Feb 2022. Prior to joining Oncorus, Dr. Goldberg served as Senior Medical Director of H3 Biomedicine, a developer of genomics-based cancer therapies. While at H3 Biomedicine, he supervised the clinical development of H3B-8800, the first-in-human spliceosome modulator. Previously, Dr. Goldberg held clinical roles in cancer drug development, leading the pediatric oncology Phase 1 program at the University of Miami and working as Medical Director for Agenus. His immunotherapy experience includes first-in-human neo-antigen vaccines, dendritic cell vaccine and GVAX trials, as well as checkpoint inhibitors and costimulatory agonists. Dr. Goldberg is also a pediatric oncologist with 15 years of experience treating children with cancer and enrolling patients in clinical trials. Dr. Goldberg received his pediatric hematology oncology training from the Dana-Farber Cancer Institute and Children’s Hospital Boston and his general pediatrics training from the University of Rochester. Dr. Goldberg holds an M.D. from the University of Massachusetts Medical School and a A.B. in Biological Sciences from the University of Chicago. In addition, Dr. Goldberg is a Medical Advisory Board Member for the Sarcoma Foundation of America.

 

Alberto Gabizon, MD, founder and Chief Scientific Advisor of Lipomedix is Professor of Oncology (Shaare Zedek Medical Center, The Hebrew University of Jerusalem) and a renowned scientist and clinician in the field of nanomedicine and cancer therapy. As co- inventor and co-developer of Doxil®, a smart chemotherapy "drug carrier" with tumor- targeting properties and important safety advantages, Prof. Gabizon is one of the few scientists intimately familiar with the successful development and the clinical implementation of liposomal drugs. His most recent invention currently in clinical studies is Promitil® (pegylated liposomal mitomycin-C prodrug). Dr. Gabizon received his M.D. from the University of Granada in Spain, and his Ph.D. from the Weizmann Institute of Science in Israel. His clinical and research contributions in the field of liposomes and targeting therapy of cancers have been recognized by various awards, among them the 2010 Alec Bangham Lifetime Achievement Award at the Liposome Research Days Conference in Vancouver, Canada, and the 1997 Kaye Innovation Award.

 

Eliyahu Shalom has served as Chief Executive Officer of Lipomedix from January 2023 to October 2024. Mr. Shalom has been with the Company since June 2021 serving as Managing Director of Business Development. Mr. Shalom served as Senior Project Manager, Digital & Technology, of IDW Publishing from June 2020 to February 2021. Mr. Shalom also worked in the Israeli startup hub Tel Aviv for Zirra.CO, LTD., a fintech company, initially as a Project Manager, from November 2018 to April 2020. Mr. Shalom’s prior roles provided him with extensive experience in project management and problem solving. He earned his bachelor’s degree from Brooklyn College in 2016 and his master’s in Business Administration from Bar- Ilan University in June 2023.

 

Jacob Serfati, representing Kepler Holdings, expert investor, in the Latin-American pharmaceutical industry and founder of Jayor Pharmaceutical Co., from Miami, FL. 

 

Rami Kremien, co-founder of Lipomedix, business investor with 40 years of experience in the banking industry and in finance, tech and oil exploration.